Literature DB >> 30418558

Value-Based Health Care in Inflammatory Bowel Disease.

Zunirah Ahmed1, Shashank Sarvepalli2, Ari Garber3, Miguel Regueiro3, Maged K Rizk3.   

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disease associated with significant resource utilization and health care burden. It is emerging as a global disease affecting an increasing proportion of the population. Along with evolving epidemiological trends, the paradigm of managing IBD has also changed. With a burgeoning repertoire of therapeutic options, improved use of health informatics, and emphasis on health care value, the treatment paradigm for IBD has experienced seismic shifts. In this review, we focused on value-based health care (VBHC)-a health care model that emphasizes monitoring outcomes to emphasize patient-centered, cost-effective IBD patient care. Several quality initiatives have been developed worldwide, and successful models of care were created for proper implementation of these initiatives. Although there are significant challenges to scale these models to a national level, it is still possible to successfully implement VBHC models within health systems to improve the quality of care provided to patients with IBD.
© 2018 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  health care quality; inflammatory bowel disease; value-based health care

Mesh:

Year:  2019        PMID: 30418558     DOI: 10.1093/ibd/izy340

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  1 in total

1.  National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States.

Authors:  Nghia H Nguyen; Rohan Khera; Parambir S Dulai; Brigid S Boland; Lucila Ohno-Machado; William J Sandborn; Siddharth Singh
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 7.290

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.